Open Access Open Access  Restricted Access Subscription or Fee Access

System intervention in community pharmacy setting: Leading to better patient care through reducing harm associated with coprescribing benzodiazepines and opioids

Angelina Vascimini, PharmD, Kevin Duane, PharmD, Stacey Curtis, PharmD

Abstract


Objective: The opioid epidemic is frequently discussed including the staggering numbers involved with coprescribing opioids and benzodiazepines associated with death. Community pharmacists, with the help of a system intervention, have a unique opportunity to help reduce the coprescribing of benzodiazepines and opioids and reduce the associated risk of death.

Design: A single center retrospective chart review was conducted after a system intervention was placed, as a quality improvement project, from November 2019 to May 2020.

Setting: Independent community pharmacy.

Patients/participants: Data included demographics, dosing of each medication pre- and post-intervention, and naloxone status.

Main outcome(s) measures: The primary outcome evaluated was reduction in dose/discontinuation of these prescriptions. The secondary outcome evaluated was the number of naloxone prescriptions ordered per protocol and picked up.

Results: The primary outcome did not show statistical difference; however, the secondary outcomes showed statistical significance.

Conclusion: In conclusion, community pharmacists, with the help of evolving technologies, can reduce harm associated with the coprescribing of benzodiazepines and opioids.


Keywords


benzodiazepine, opioid, community pharmacy, reduce harm

Full Text:

PDF

References


Tsuyuki RT, Beahm NP, Okada H, et al.: Pharmacists as accessible primary health care providers: Review of the evidence. Can Pharm J. 2018; 151(1): 1-5. DOI: 10.1177/1715163517745517.

Hippensteele A: The value of the accessibility of pharmacists in their communities. Pharmacy Times, June 26, 2020. Available at www.pharmacytimes.com/interviews/the-value-of-the-accessibility-of-pharmacists-in-their-communities. Accessed July 6, 2020.

National Institute on Drug Abuse: Benzodiazepines and opioids. March 15, 2018.

Dasgupta N, Funk MJ, Proescholdbell S, et al.: Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016; 17(1): 85-98. DOI: 10.1111/pme.12907.

Dowell D, Haegerich TM, Chou R: CDC guideline for prescribing opioids for chronic pain—United States. MMWR Recomm Rep. 2016; 65(1) :1-49. DOI: 10.15585/mmwr.rr6501e1.

Secretary, HHS Office, and Office of the Surgeon General: US surgeon general's advisory on naloxone and opioid overdose. HHS.gov, US Department of Health and Human Services, April 5, 2018. Available at www.hhs.gov/surgeongeneral/priorities/opioids-and-addiction/naloxone-advisory/index.html. Accessed July 6, 2020.

Bingham JM, Taylor AM, Boesen KP, et al. Preliminary investigation of pharmacist-delivered, direct-to-provider interventions to reduce co-prescribing of opioids and benzodiazepines among a Medicare population. Pharmacy. 2020; 8(1): 25. DOI: 10.3390/pharmacy 8010025.

Bach P, Hartung D: Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. Addict Sci Clin Pract. 2019; 14: 30. DOI: 10.1186/s13722-019-0158-0.

Dempsey C: Patient satisfaction scores: Optimizing the patient and clinician experience. Press Ganey, May 27, 2016. Available at www.pressganey.com/About/News/Patient-Satisfaction-Scores-Optimizing-The-Patient-And-Clinician-Experience. Accessed July 13, 2020.




DOI: https://doi.org/10.5055/jom.2021.0679

Refbacks

  • There are currently no refbacks.